Form 8-K - Current report:
SEC Accession No. 0001213900-22-029411
Filing Date
2022-05-25
Accepted
2022-05-25 09:10:55
Documents
15
Period of Report
2022-05-25
Items
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 CURRENT REPORT ea160541-8k_citius.htm   iXBRL 8-K 28576
2 PRESS RELEASE DATED MAY 25, 2022 ea160541ex99-1_citius.htm EX-99.1 14674
3 GRAPHIC ex99-1_001.jpg GRAPHIC 10975
  Complete submission text file 0001213900-22-029411.txt   281179

Data Files

Seq Description Document Type Size
4 XBRL SCHEMA FILE ctxr-20220525.xsd EX-101.SCH 3755
5 XBRL DEFINITION FILE ctxr-20220525_def.xml EX-101.DEF 26834
6 XBRL LABEL FILE ctxr-20220525_lab.xml EX-101.LAB 36824
7 XBRL PRESENTATION FILE ctxr-20220525_pre.xml EX-101.PRE 25456
9 EXTRACTED XBRL INSTANCE DOCUMENT ea160541-8k_citius_htm.xml XML 5353
Mailing Address 11 COMMERCE DRIVE 1ST FLOOR CRANFORD NJ 07016
Business Address 11 COMMERCE DRIVE 1ST FLOOR CRANFORD NJ 07016 (908) 967-6676
Citius Pharmaceuticals, Inc. (Filer) CIK: 0001506251 (see all company filings)

EIN.: 273425913 | State of Incorp.: NV | Fiscal Year End: 0930
Type: 8-K | Act: 34 | File No.: 001-38174 | Film No.: 22959355
SIC: 2834 Pharmaceutical Preparations